JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Animal models
BALB/cJ mice infected with influenza virus and superinfected with Streptococcus pneumonia (S. pneumoniae)
Dosage form
60 mg/kg
Twice daily by intraperitoneal route for 7 days
Applications
In the model, clindamycin therapy used either alone (survival rate, 82%) or in combination with ampicillin (80%) performed significantly better than ampicillin therapy (56%). Improved survival appeared to be mediated by decreased inflammation manifested as lower levels of inflammatory cells and proinflammatory cytokines in the lungs and by observation of less-severe histopathologic findings. Thus, treatment with protein synthesis inhibitor clindamycin could improve outcomes of secondary bacterial pneumonia after influenza.
Note
The technical data provided above is for reference only.
References:
1. Karlström A, Boyd KL, English BK, et al. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. The Journal of Infectious Diseases, 2009, 199(3): 311-319.